药物洗脱微球化疗栓塞术（DEB-TACE）与放射性栓塞术（TARE）治疗结直肠癌肝转移患者的疗效及预后比较
Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases.
作者信息
Mokkarala Mahati, Noda Christopher, Malone Christopher, Ramaswamy Raja, Akinwande Olaguoke
机构信息
Washington University in St. Louis School of Medicine, St. Louis, MO, U.S.A.
Department of Radiology, Mallinckrodt Institute of Radiology, St. Louis, MO, U.S.A.
出版信息
Anticancer Res. 2019 Jun;39(6):3071-3077. doi: 10.21873/anticanres.13442.
BACKGROUND
To compare outcomes for patients with colorectal cancer liver metastases (CRCLM) treated by drug-eluting bead chemoembolization (DEB-TACE) or radioembolization (TARE).
PATIENTS AND METHODS
A single-center retrospective review was carried out on 202 patients with CRCLM, treated by DEB-TACE (n=47) or TARE (n=155) patients. Propensity-matching yielded 44 pairs. Paired statistical analysis was performed on matched pair demographics, treatment response, and survival.
RESULTS
Patients treated with DEB-TACE had worse extra-hepatic metastasis (68.1 vs. 47.7%, p=0.014) and ≥10 liver lesions (42.2 vs. 68.8%, p=0.001). Matched patients treated with DEB-TACE had a trend towards worse toxicity (27% vs. 9.1% (p=0.057). Index DEB-TACE treatment was not a prognostic factor for overall survival (hazard ratio=0.94, 95% confidence intervaI=0.54-1.65; p=0.83).
CONCLUSION
In the matched CRCLM cohort, there was a trend towards worse toxicity post-DEB-TACE treatment, but it was not an independent prognostic factor for survival.
背景
比较接受药物洗脱微球化疗栓塞术（DEB-TACE）或放射性栓塞术（TARE）治疗的结直肠癌肝转移（CRCLM）患者的治疗结果。
患者与方法
对202例接受DEB-TACE（n = 47）或TARE（n = 155）治疗的CRCLM患者进行单中心回顾性研究。倾向评分匹配产生44对。对匹配对的人口统计学、治疗反应和生存情况进行配对统计分析。
结果
接受DEB-TACE治疗的患者肝外转移情况更差（68.1%对47.7%，p = 0.014），且肝脏病灶≥10个的比例更高（42.2%对68.8%，p = 0.001）。接受DEB-TACE治疗的匹配患者毒性有加重趋势（27%对9.1%，p = 0.057）。首次DEB-TACE治疗并非总生存的预后因素（风险比=0.94，95%置信区间=0.54 - 1.65；p = 0.83）。
结论
在匹配的CRCLM队列中，DEB-TACE治疗后毒性有加重趋势，但并非生存的独立预后因素。
Zotero 插件